الفهرس | Only 14 pages are availabe for public view |
Abstract Varicose veins are a very common problem all over the world. Surgery has been the gold standard treatment for many years, but now there are less invasive options are available and sometimes more efficient as sclerotherapy. Sclerotherapy involves the injection of a liquid or foam substance that interacts with the vessel lining, causing a controlled thrombophlebitic reaction. This response, if successful, leads to the production of a fibrous cord.Although sclerotherapy is generally considered safe, there are certain publications that reveal the presence of serious adverse events of sclerotherapy and this leads to safety issues Food and Drug Administration (FDA) approved certain sclerosants such as sodium morrhuate, ethanolamine oleate, and sodium tetradecyl sulphate. The purpose of this study was to examine the efficacy of 1% polidocanol as a sclerosant for Telegenctasia versus ethanolamine oleate regarding safety concerns and efficacy. A prospective randomized controlled study was conducted at General Surgery Department, Menoufia University Hospital. We admitted 100 patients distributed into two groups:. First group treated with Aethoxysclerol (50 patients) Second group: patients treated with diluted Ethanolamine oleate (50 patients). we used 1 ml of aetoxy per session (180 ml for all sessions) and 0.7 ml of Ethanolamine olate (99.5 ml for all sessions) Regarding complications of injection: no significant stastical difference between 2 groups regarding: itching, superficial thrombophelibitis, pigmentation and ulcer, there was significant stastical difference between 2 groups regarding pain at injection site. For many years, the use of ethanolamine oleate has many limitations because of the high incidence of after-injection side effects such as: - skin hyperpigmentation due to hemosiderin deposition, injection pain, itching after the procedure,skin necrosis, superficial thrombophlebitis, anaphylaxis and deep vein thrombosis and pulmonary embolism In this study we used a new protocol by diluting ethanolamine oleate to 25% concentration and we found great decline in incidence of complications: No evidence of DVT and very low incidence of ulceration and superficial thrombophlebitis, beside having relatively low cost compared to aethoxysclerol. This gives diluted ethanolamine oleate equal chance as aethoxysclerol for use as scleroscant agent in treatment of telangiectasia. |